Suppr超能文献

多药耐药癌细胞中小窝及小窝成分的上调

Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells.

作者信息

Lavie Y, Fiucci G, Liscovitch M

机构信息

Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel.

出版信息

J Biol Chem. 1998 Dec 4;273(49):32380-3. doi: 10.1074/jbc.273.49.32380.

Abstract

Cancer chemotherapy often results in the development of multidrug resistance (MDR), which is commonly associated with overexpression of P-glycoprotein (P-gp), a plasma membrane drug efflux ATPase. It was shown recently that glycosphingolipids are elevated in MDR cells. Sphingolipids are major constituents of caveolae and of detergent-insoluble, glycosphingolipid-rich membrane domains. Here we report that multidrug-resistant HT-29 human colon adenocarcinoma cells exhibit a 12-fold overexpression of caveolin-1, a 21-kDa coat/adaptor protein of caveolae. Similar observations were made in adriamycin-resistant MCF-7 human breast adenocarcinoma cells. Caveolin-2 expression is also up-regulated in MCF-7-AdrR cells, but neither caveolin-1 nor caveolin-2 were detected in MCF-7 cells stably transfected with P-gp. The up-regulation of caveolins is associated with a 5-fold increase in the number of caveolae-like structures observed in plasma membrane profiles of HT-29-MDR cells and with the appearance of a comparable number of caveolae in MCF-7-AdrR cells. A significant fraction (approximately 40%) of cellular P-gp is localized in low density detergent-insoluble membrane fractions derived from either HT-29-MDR or MCF-7-AdrR cells. The distribution of recombinant P-gp in stably transfected MCF-7 cells was similar, even though these cells do not express caveolins and are devoid of caveolae. The possibility that caveolae contribute to the multidrug resistance and thus are co-selected with P-gp during the acquisition of this phenotype is discussed.

摘要

癌症化疗常常导致多药耐药性(MDR)的产生,这通常与P-糖蛋白(P-gp)的过度表达有关,P-糖蛋白是一种质膜药物外排ATP酶。最近有研究表明,糖鞘脂在多药耐药细胞中含量升高。鞘脂是小窝以及去污剂不溶性、富含糖鞘脂的膜结构域的主要成分。在此我们报告,多药耐药的HT-29人结肠腺癌细胞中,小窝蛋白-1(一种21 kDa的小窝包被/衔接蛋白)呈现12倍的过度表达。在阿霉素耐药的MCF-7人乳腺腺癌细胞中也有类似发现。小窝蛋白-2的表达在MCF-7-AdrR细胞中也上调,但在稳定转染P-gp的MCF-7细胞中未检测到小窝蛋白-1和小窝蛋白-2。小窝蛋白的上调与HT-29-MDR细胞质膜轮廓中观察到的类小窝结构数量增加5倍以及MCF-7-AdrR细胞中出现相当数量的小窝有关。来自HT-29-MDR或MCF-7-AdrR细胞的低密度去污剂不溶性膜组分中,有相当一部分(约40%)细胞P-gp定位于此。重组P-gp在稳定转染的MCF-7细胞中的分布情况类似,但这些细胞不表达小窝蛋白且没有小窝。本文讨论了小窝是否有助于多药耐药,从而在获得该表型过程中与P-gp共同被选择的可能性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验